Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.

A revolutionary gene therapy treatment in London has improved the vision of children suffering from a rare genetic disorder, ...

MeiraGTx stock rose after publishing promising results from the first human trial using gene therapy to treat AIPL1-associated severe retinal dystrophy in children. Read more here.

Like recombinant DNA before it, gene editing has the potential to transform medicine, agriculture and more. CRISPR is now used by thousands of biologists in labs across the globe. A revolution in food ...

Doctors harvest stem cells from the patient’s bone marrow and then send them off to a lab, where CRISPR is used to turn up the production of another, functional version of haemoglobin. This version is ...

Pfizer will end the global commercialisation of its haemophilia gene therapy Beqvez (fidanacogene elaparvovec) amid low ...

Bluebird bio went public in 2013, raising approximately $116m through its IPO. The company has developed three US Food and Drug Administration (FDA)-approved gene therapy products, including Zynteglo ...

A new inhalable gene therapy for cystic fibrosis (CF) has entered Phase I clinical trials, a major milestone on the journey ...

The pioneering gene therapy developer will be acquired by investment firms Carlyle Group and SK Capital for a fraction of ...

By Sneha S K (Reuters) -Gene therapy maker bluebird bio on Friday agreed to be taken private by Carlyle Group and SK Capital ...

The American Cancer Society estimates that 83,000 new cases of bladder cancer will be diagnosed this year, with almost 17,000 ...

The Carlyle Group and SK Capital Partners have agreed to acquire bluebird bio, Inc, a Somerville, Massachusetts-based gene therapy firm, in a take-private deal. According to terms of the agreement, ...